Technologies

Bivalve mollusc shells are made mainly of CaCO₃ (ca 95%), with a small fraction of organic material. If from these shells this mineral is retrieved, they could become a renewable and sustainable “mine” of a “blue” CaCO₃. Bivalve mollusc shells, also after the removal of the animal flesh, maintain a certain quantity of organic substances, part in the muscle and part in the shell.

The technology, developed by CNR-ICB, is based on an innovative bioprocess called "Caphnophilic (CO2-requiring) Lactic Fermentation (CLF)”, developed in the hyperthermophilic bacterium Thermotoga neapolitana (EP patent: EP2948556B1), which allows the production of "green" hydrogen and capture and valorization of CO2 in L -lactic acid (98% e.e.).

The development of genome editing tools has revolutionized the way we think and deal with genetics. The use of Cas9 or its variants allows modifications of specific sites in the human genome by inducing deletions and insertions in a more or less controlled way. In recent years, a new class of tools for genome editing has emerged: the base editors (BE), which result from the fusion of a modified Cas9, which serves to direct the BE to the target, and an active deaminase acting on the DNA, which mediates the C> T or A> G editing.

Aptamers, short structured single-stranded oligonucleotides binding at high affinity to a given target protein, are selected from large combinatorial libraries through repeated cycles of incubation of the library with the target, recovery and amplification of target-bound oligonucleotides (SELEX technology, Systematic Evolution of Ligands by EXponential enrichment). SELEX can be applied to select aptamers against a known target protein or against a specific cell phenotype, without any prior knowledge of the specific target, leading to new biomarkers discovery.

The technology we participate to develop, called "Zinc-Finger Artificial Transcription Factors (ZF-ATFs)", allows to design, realize and select artificial genes coding for proteins capable of recognizing and binding "potentially" any DNA sequence. We used ZF-ATF technology to reprogram the expression of "beneficial" genes capable of efficiently counteracting the negative effect of mutated genes related to rare diseases.

B-ME developed the first thermoplastic composite electrode film based on bio-derived and biodegradable polyesters and carbon nano-fibers. It is metal-free, highly electrically conductive and possess good thermo-mechanical properties, a challenging combination of three features in a single product. This is the first-of-its-kind product, as, to the best of our knowledge, no thermoplastic biobased electrode film has been effectively produced and used so far.

The present invention relates to the biomedical sector of the treatment of lung diseases and related symptoms. In particular, the present invention provides compositions and methods based on the use of selected polymeric biomaterials, in combination with stem cells and/or their secretome, capable of synergistically improving the development, regeneration and repair of chronic lung injuries and related symptoms.

A virtuous multi-step biorefinery platform to convert urban biowaste into valuable molecules, not disregarding renewable energy and digestate production. The strategy is based on the integration of a thermal pretreatment capable of significantly increasing the fraction of fermentable organic carbon, in order to furthermore change the status of the feedstock to become more suitable for production of a) high-value bio-based molecules, b) biomethane and c) hygienized digestate to be recycled as biofertilizer.

The herein described technology aims at the development of a platform of injectable hydrogels for application as drug carriers for localized delivery or in the regenerative medicine field. The use of ad-hoc synthesized poly(ether urethane)s (PEUs) as hydrogel forming materials is a common property which characterizes all the systems belonging to this platform.

Lifeshell is an anti-seismic furniture construction concept, which can be used for making wardrobes, tables, desktops, beds. It’s made by timber based panels: highly resistant and flexible, relatively lightweight and inexpensive. Lifeshell benefits from the natural wood elasticity and from smart connections for dissipating the great impact energies occurring during an earthquake. Lifeshell has been designed for resisting partial building collapses, and to provide a safe shell where inhabitants can find refuge.

Integrative omics has posed new challenges in modern precision medicine, particularly in oncology, including i) the identification of new tumor markers for early, precise, and non-invasive diagnostics, and ii) the discovery of innovative molecular targets for therapeutic applications. Our studies on medulloblastoma, a highly malignant childhood tumor, have contributed to identifying RNA molecules that meet these criteria.

The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples).

An innovative approach for the treatment of diabetic and venous ulcers, characterized by a difficult healing process and therefore at potential risk of infection and therefore of hospitalization and amputation of the limb, is represented by the local administration of "bioactive" factors through the use of synthetic and/or biological matrices that allow a gradual and controlled release in order to obtain a better and faster healing.

The object of the technology is the development of a transferable methodology from the laboratory scale to the pilot scale to be validated in the industrial setting for the treatment of basic waste of natural polymers of agro-food or manufacturing industry.

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.